Literature DB >> 35758724

Evaluation of Clinical Metrics for Identifying Defective Physiologic Responses to Hypoglycemia in Long-Standing Type 1 Diabetes.

Anneliese J Flatt1, Elizabeth Chen1, Amy J Peleckis1, Cornelia Dalton-Bakes1, Huong-Lan Nguyen1, Heather W Collins1, John S Millar1,2,3, Robert J Gallop4,5, Michael R Rickels1,2,6.   

Abstract

Repeated hypoglycemia exposure leads to impaired awareness of hypoglycemia (IAH) and the development of defective counterregulatory responses. To date, only pancreas or islet transplantation has demonstrated normalization of hypoglycemia awareness and the endogenous glucose production (EGP) response to defend against insulin-induced hypoglycemia in long-standing type 1 diabetes (T1D). This study aims to validate clinical metrics of IAH (Clarke score), hypoglycemia severity (HYPO score), glycemic lability (lability index), and continuous glucose monitoring (CGM) as predictors of absent autonomic symptom (AS) recognition and defective glucose counterregulation during insulin-induced hypoglycemia, thus enabling early identification of individuals with compromised physiologic defense against clinically significant hypoglycemia. Forty-three subjects with mean ± standard deviation age 43 ± 13 years and T1D duration 28 ± 13 years, including 32 with IAH and 11 with hypoglycemia awareness (Aware), and 12 nondiabetic control subjects, underwent single-blinded randomized-paired hyperinsulinemic-euglycemic and hypoglycemic clamp experiments. Receiver operating characteristic (ROC) curves and sensitivity analyses were performed to assess metric prediction of absent AS recognition and defective EGP responses to hypoglycemia. Clarke score and CGM measures of hypoglycemia exposure demonstrated good ability to predict absent AS recognition (area under the curve ≥0.80). A composite threshold of IAH-Clarke ≥4 with ROC curve-derived thresholds for CGM measures of hypoglycemia exposure showed high specificity and predictive value in identifying an absent AS response during the hypoglycemic clamp. Metrics demonstrated poor ability to predict defective glucose counterregulation by the EGP response, which was impaired even in the Aware group. Screening for IAH alongside assessment of CGM data can increase the specificity for identifying individuals with absent hypoglycemia symptom recognition who may benefit from further intervention.

Entities:  

Keywords:  Autonomic symptoms; Continuous glucose monitoring; Glucose counterregulation; Hypoglycemia unawareness

Mesh:

Substances:

Year:  2022        PMID: 35758724      PMCID: PMC9529296          DOI: 10.1089/dia.2022.0103

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   7.337


  55 in total

1.  Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.

Authors:  Lutz Heinemann; Guido Freckmann; Dominic Ehrmann; Gabriele Faber-Heinemann; Stefania Guerra; Delia Waldenmaier; Norbert Hermanns
Journal:  Lancet       Date:  2018-02-16       Impact factor: 79.321

Review 2.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.

Authors:  M H Zweig; G Campbell
Journal:  Clin Chem       Date:  1993-04       Impact factor: 8.327

3.  State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018.

Authors:  Nicole C Foster; Roy W Beck; Kellee M Miller; Mark A Clements; Michael R Rickels; Linda A DiMeglio; David M Maahs; William V Tamborlane; Richard Bergenstal; Elizabeth Smith; Beth A Olson; Satish K Garg
Journal:  Diabetes Technol Ther       Date:  2019-01-18       Impact factor: 6.118

4.  Defining High Glycemic Variability in Type 1 Diabetes: Comparison of Multiple Indexes to Identify Patients at Risk of Hypoglycemia.

Authors:  Ana María Gómez; Diana Cristina Henao; Angélica Imitola Madero; Lucía B Taboada; Viviana Cruz; María Alejandra Robledo Gómez; Martin Rondón; Oscar Muñoz-Velandia; Maira García-Jaramillo; Fabian Mauricio León Vargas
Journal:  Diabetes Technol Ther       Date:  2019-06-20       Impact factor: 6.118

5.  Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction.

Authors:  A Mitrakou; C Ryan; T Veneman; M Mokan; T Jenssen; I Kiss; J Durrant; P Cryer; J Gerich
Journal:  Am J Physiol       Date:  1991-01

6.  Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry.

Authors:  Ruth S Weinstock; Dongyuan Xing; David M Maahs; Aaron Michels; Michael R Rickels; Anne L Peters; Richard M Bergenstal; Breanne Harris; Stephanie N Dubose; Kellee M Miller; Roy W Beck
Journal:  J Clin Endocrinol Metab       Date:  2013-06-12       Impact factor: 5.958

7.  Recurrent hypoglycemia inhibits the counterregulatory response by suppressing adrenal activity.

Authors:  Yunbing Ma; Qian Wang; Debria Joe; Manqi Wang; Matthew D Whim
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

8.  Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation.

Authors:  Edmond A Ryan; Tami Shandro; Kristy Green; Breay W Paty; Peter A Senior; David Bigam; A M James Shapiro; Marie-Christine Vantyghem
Journal:  Diabetes       Date:  2004-04       Impact factor: 9.461

9.  Differentiating Hypoglycemia Awareness Status from Hypoglycemia Experience in Tools for Measuring Impaired Awareness of Hypoglycemia.

Authors:  Eduardo Sepúlveda; Rui Poínhos; Gil Nata; Davide Carvalho; João Sérgio Neves; Daniela Seixas; Pratik Choudhary; Selene G Vicente; Stephanie A Amiel
Journal:  Diabetes Technol Ther       Date:  2020-07       Impact factor: 6.118

10.  A Comparison of Validated Methods Used to Assess Impaired Awareness of Hypoglycaemia in Type 1 Diabetes: An Observational Study.

Authors:  Kshitiz Ghandi; Beatrice Pieri; Anne Dornhorst; Sufyan Hussain
Journal:  Diabetes Ther       Date:  2020-11-20       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.